Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSTANT-2
NCT07842185Phase 3Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Nov 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tirofiban in ischemic stroke (3 arms), sponsored by Xinqiao Hospital. Primary endpoint: Proportion of patients with modified Rankin Scale score 0-1 at 90 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
tirofiban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07842185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07842185.